To explore early (within 72 h) vs delayed enteral nutrition (EN) therapy for patients with acute pancreatitis (AP). SUBJECTS/METHODS: A total of 93 patients were allocated to two groups: early enteral nutrition (EEN) group (started within 72 h after onset) and delayed enteral nutrition (DEN) group (started beyond 72 h but within 7 days after onset). Baseline parameters and scores were recorded on admission and on day 3 after the initiation of EN therapy, as were the clinical outcome variables. RESULTS: Hospital mortality, length of stay, number of patients requiring mechanical ventilation and incidence of pancreatic infection in the EEN group were significantly lower than those in the DEN group; all six reported deaths were in the DEN group. In the DEN group, more patients suffered from sepsis, shock or acute kidney injury, and more patients required surgical intervention or continuous renal replacement therapy. On day 3 after EN therapy was initiated, the acute physiology and chronic health evaluation II scores, sequential organ failure assessment scores, C-reactive protein levels and the incidence of bowel wall thickening were lower in the EEN group than in the DEN group. The time when EN therapy was initiated was a prognostic variable for pancreatic infection (odds ratio, 24.08; P = 0.014). CONCLUSIONS: Compared with the DEN therapy, EEN therapy can accelerate the recovery of disturbed homeostasis, reduce the incidence of pancreatic infection and improve the clinical outcomes of AP patients. For AP patients, EN therapy should be initiated within 72 h after onset.
INTRODUCTION
Acute pancreatitis (AP), a common disease of the gastrointestinal tract, is characterised by hypercatabolism with a negative nitrogen balance, which leads to increased infections, organ dysfunction and other ailments. Thus nutrition therapy is very important in managing AP. 1 Compared with no nutrition therapy, artificial feeding, including enteral nutrition (EN) or parenteral nutrition (PN), can reduce the risk of death in patients with AP. 2 As early as 1973, 3 AP became one of the first non-surgical indications for PN, and EN was introduced into AP management in the 1990s. 4 Thus many AP guidelines now suggest that if patients with mild-tomoderate AP have been nil per os for 5-7 days, nutrition therapy is necessary, and early nutrition therapy is an absolute indication of severe and critical AP. 1, [5] [6] [7] Compared with PN, enteral feeding has many advantages. 8 The protective role of EN has been demonstrated in AP models, 9 and many randomised controlled clinical trials and meta-analyses have established that EN reduces the risk of pancreatic infection and mortality in patients with severe AP compared with PN. [10] [11] [12] [13] [14] [15] Therefore nutrition guidelines for AP and other critical illnesses recommend EN as the first choice; even with feeding intolerance, regular trials with small amounts of EN should be considered. 16 However, to date, no consensus has been reached regarding when to administer EN, although related research has suggested that 48 h after admission may be the optimal cutoff point. [17] [18] The interval from disease onset to hospital admission has been unclear in previous studies, however, which has likely contributed to biased results. 19 Furthermore, we believe that the time to begin EN therapy in AP patients should be based on the pathophysiology course, especially regarding any intestinal damage from systemic inflammatory response syndrome (SIRS). A study shows that the gut barrier is damaged in the early phase of AP, and intestinal permeability increases as early as 48-72 h from its onset. 20 In addition, another recent study showed that bacterial DNA could be detected in the peripheral blood of 45.5% of patients with AP on day 4 or 5 after the AP was diagnosed, and the detection rate was positively correlated with the acute physiology and chronic health evaluation (APACHE) II score. 21 Therefore, we believe that 72 h after onset should be regarded as the cutoff point for the study. However, no related research has concentrated on the comparison between EN administration within 72 h after AP onset with that beyond 72 h. Thus this retrospective study of AP patients who were admitted to our department within 72 h after onset attempted to compare early enteral nutrition (EEN) (within 72 h after onset) with delayed enteral nutrition (DEN) (beyond 72 h but within 7 days after onset), paying primary attention to the clinical outcome differences between them.
MATERIALS AND METHODS Patients
A retrospective study was performed of 1111 consecutive patients with AP who were admitted to the surgical intensive care unit of the Institute of General Surgery, Jinling Hospital, Nanjing, People's Republic of China from 1 January 2008 to 31 July 2013. The diagnosis of AP was based on the Atlanta criteria formulated in 1992. The exclusion criteria were as follows: admission to our department beyond 72 h after onset, o18 years, coexisting chronic gastrointestinal or immune system diseases, previous gastrointestinal surgery, AP confirmed during laparotomy for acute abdominal pain, AP in pregnancy, incomplete information, or haemodynamic instability on admission. Ultimately, a total of 93 patients were enrolled in our study: 46 patients were in the EEN group, and 47 patients matched for age and sex (stratified random sampling) served as the DEN group. A nasojejunal feeding tube was inserted, guided by X-ray or endoscopy, and then a 500-ml glucose and sodium chloride injection was administered into the gut through the nasojejunal feeding tube on the same day. Subsequent nutrition instructions were given by the physicians themselves with certain basic principles: permissive underfeeding at the beginning (10-15 kcal/kg/d), from slow to fast, and from peptide-based formula (Peptisorb, Nutricia Ltd, Wuxi, China) to whole protein formula (Nutrison Fibre, Nutricia Ltd, Wuxi, China). In the event of feeding intolerance (such as nausea, vomiting, diarrhoea, abdominal distension, and so on), measures were taken, including slowing down the infusion speed, warming the enteral nutrient and/or including prokinetics. Along with nutrition therapy, all of the AP patients received standard management, including fasting, exocrine pancreatic suppression, fluid resuscitation, oxygen administration, antibiotic prophylaxis and serous cavity puncture, as well as percutaneous cholecystostomy when necessary. All patients studied received a contrast-enhanced computed tomography (CECT) scan within 3 days after admission and a second CT scan about on day 10 after treatment.
Data collection
Some of the baseline values on admission were collected retrospectively, including (1) demographic data: sex, age, body mass index, and AP aetiology; (2) routine blood and biochemical parameters: white blood cell count, platelet count, haematocrit, amylase, glucose, calcium, creatinine, blood urea nitrogen, total bilirubin, aspartate aminotransferase; (3) APassociated scores: Ranson score, pancreatitis outcome prediction (POP) score, and Balthazar CT severity index (CTSI) score.
Certain parameters before and after initiating EN therapy were also recorded and compared: (1) five parameters on the first 3 days after admission and on day 3 after initiating EN therapy: APACHE II score, Sequential Organ Failure Assessment (SOFA) score, serum albumin and C-reactive protein (CRP) concentration, and Capillary Leakage Index (CLI); and (2) the incidence of bowel wall thickening on the first CECT images after admission and after initiating EN therapy.
Ultimately, clinical outcomes between the two groups were evaluated and compared, including (1) hospital mortality; (2) length of stay; (3) number of patients suffering from SIRS for over 48 h; (4) number of patients receiving mechanical ventilation; (5) number of patients receiving continuous renal replacement therapy (CRRT); (6) number of patients receiving surgical intervention; (7) pancreatic infection; (8) extra-pancreatic infection; (9) local complications: necrosis, acute peripancreatic fluid collection, acute necrosis collection, walled-off necrosis, and pseudocysts; and (10) systemic complications: acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), sepsis, shock, organ failure, and multiple organ dysfunction syndrome (MODS).
Definitions and statement
The POP score integrated six variables within the first 24 h after admission to produce a model for predicting prognosis: arterial pH, age, serum urea, mean arterial pressure, PaO 2 /FiO 2 ratio, and total serum calcium. 22 The Capillary Leakage Index, defined as the C-reactive protein over albumin ratio as a capillary leak parameter, has been demonstrated to be a good indicator of illness severity. 23 Bowel wall thickening is very common on the CT images of patients with gastrointestinal diseases for various reasons, such as oedema, inflammatory bowel diseases, gastrointestinal bleeding, ischaemia, neoplasm, infection and others, and is defined as thickness of ⩾ 3 mm on CECT images. 24 For patients in the early phase of AP, without chronic gastrointestinal or immune system diseases, inflammatory oedema induced by SIRS was the main mechanism. Pancreatic infection was diagnosed when a bacterial culture of peripancreatic fluid was positive and body temperature increased repeatedly. 25 The diagnosis of local complications was based on the most recent AP classification. 26 Organ failure was determined according to the modified Marshall scoring system. MODS was defined as the dysfunction of ⩾ 2 organs at the same time. The diagnoses of SIRS, sepsis and shock were based on 2012 international guidelines for management of severe sepsis and septic shock. 27 
Statistical analysis
All of the quantitative variables are expressed as medians and interquartile ranges unless otherwise stated, and the categorical variables are expressed as the numbers and percentages. A one-sample K-S test was used to determine whether the quantitative variables obeyed parametric distribution or not. The Student's t-test was used to compare the quantitative variables with the parametric distribution between the two groups, and the Mann-Whitney U test was used for those with nonparametric distribution. The differences between qualitative variables were determined using the Chi-square test. Po 0.05 was considered statistically significant. A stepwise logistic regression analysis was used to identify the prognostic factors of pancreatic infection and mortality. First, we screened out potential prognostic variables using univariate analysis, and then those variables that were statistically significant (Po0.1) were entered into a multivariate logistic regression model, and Po0.05 was required for significance. The innocuous variables were removed when necessary. To evaluate the overall significance of the multivariate logistic regression model (discrimination), the Hosmer-Lemeshow test was performed, and the Nagelkerke coefficient of determination and the Cox and Snell R 2 were used to determine the overall consistency. The Statistical Package for the Social Sciences (SPSS, version 17.0, Chicago, IL, USA) was used for statistical analysis.
RESULTS

General characteristics
Finally, a total of 93 patients were enrolled into our study: 46 patients in the EEN group and 47 in the DEN group. The main aetiological factors of AP were biliary origin (41/93, 44%) and hyperlipidaemia (29/93, 31%). There was no difference in aetiology between the two groups, nor was there a difference with the other baseline values, including the AP severity scores (Ranson, POP, Balthazar CTSI). The baseline characteristics of the two groups are shown in detail in Table 1 .
Change before and after initialing EN therapy As presented in Table 2 , on the first 3 days after admission, there were no differences in APACHE II or SOFA scores between the two groups, as with the other AP severity scores in Table 1 . For the APACHE II score, we found a gradual decrease over the observed days (presented in Supplementary Figure S1) , and on the third day after initiating EN therapy, we found that the difference in the scores between the two groups became significant (3.0 vs 5.0; P = 0.021). For the SOFA score, although there was never a significant difference over the observed days between the two groups, a significant decrease was found in both the groups after EN therapy was initiated (EEN group:3.00 vs 1.00, P = 0.000; DEN group: 2.00 vs 1.00, P = 0.000; shown in Supplementary Figure S2) .
For serum albumin, CRP concentration, and CLI, there was no significant difference between the two groups on admission, but a gradual decrease was found during the treatment. There was never a significant difference in serum albumin concentration between the two groups over the observed days. However, for serum CRP concentration and CLI, there was a significant decrease in the EEN group after EN therapy was initiated (CRP: 123.50 vs 63.50 mg/l, P = 0.001; CLI × 10 3 : 3.77 vs 1.88, P = 0.001), but there was no significant decrease in the DEN group, as presented in Supplementary Figures S3 and S4 , respectively. A significant difference was also found between the two groups on the third day after EN therapy was initiated (CRP: 63.50 vs 115.00 mg/l, P = 0.005; CLI × 10 3 : 1.88 vs 3.42, P = 0.000), and both serum CRP concentration and CLI decreased more quickly in the EEN group.
On admission, the incidence of bowel wall thickening on the CECT images was nearly equal in the two groups (73.9% vs 74.9%, P = 1.000). After EN therapy, a significant decrease was found in both groups (EEN: 73.9% vs 8.7%, P = 0.000; DEN: 74.5% vs 31.9%, P = 0.000), as presented in Supplementary Figure S5 . However, compared with the DEN group, there were more patients whose bowel wall thickening disappeared after EN therapy in the EEN Early enteral nutrition in acute pancreatitis L Zou et al group, such that on the third day after EN therapy was initiated, there was a significant difference in the incidence of bowel wall thickening between the two groups (8.7% vs 31.9%, P = 0.009).
Clinical outcomes As presented in Table 3 , hospital mortality, length of stay, number of patients requiring mechanical ventilation and number of patients with pancreatic infection in the EEN group were significantly lower than in the DEN group (P o0.05), and all six reported deaths were in the DEN group. Moreover, in the DEN group, more patients required surgical intervention (6 patients vs 1 patient; P = 0.111) or CRRT therapy (9 vs 3 patients; P = 0.120). In the two groups, a nearly equal number of patients suffered from SIRS for over 48 h (24 vs 21 patients; P = 0.680). Additionally, a total of 15 patients had the complication of extra-pancreatic infection (16.13%, 15/93), with no significant difference between the two groups (6 vs 9 patients; P = 0.574): 6 patients (3 cases were pneumonia and 3 were bacteraemia) were in the EEN group, and 9 (3 cases were pneumonia, 4 were bacteraemia, and 2 were bacteraemia and biliary tract infection) were in the DEN group. Among local AP complications, 38 patients (40.7%) had pancreatic or peripancreatic necrosis, 17 cases in the EEN group and 21 in the DEN group (P = 0.529), and no significant difference was found in the incidence of acute necrosis collection between the two groups (14 vs 19 patients, P = 0.388). Acute peripancreatic fluid collection occurred in 29 patients (31.2%), 14 in the EEN group and 15 in the DEN group (P = 1.000), and only one patient in the DEN group had pancreatic pseudocysts. Five patients in the EEN group and one in the DEN group experienced walled-off necrosis.
For the systemic complications of AP, a nearly equal number of patients from both groups had AKI (26/93, 28.0%) and ARDS (25/93, 26.9%) . No significant differences between the two groups were noted in the percentages of AKI (9 vs 17 patients, P = 0.106), ARDS (10 vs 15 patients, P = 0.351), sepsis (2 vs 8 patients, P = 0.091), organ failure (21 vs 25 patients, P = 0.536) or MODS (8 vs 13 patients, P = 0.322), but more patients experienced these complications in the DEN group. Moreover, all five reported shocks were in the DEN group (P = 0.056).
Prognostic variables of pancreatic infection and mortality First, we concentrated on the prognostic variables for pancreatic infection. Using univariate analysis, we found that the following variables were significant predictors: age; the time when EN therapy was initiated; the APACHE II and SOFA scores on days 1-3; the Ranson score; the serum CRP level on day 3; the serum Ca 2+ level on admission to hospital; and the platelet level on admission to hospital. The final multivariate logistic regression model for pancreatic infection (logistic regression Chi-square, 42.47, P o0.001; Cox and Snell R 2 , 0.367; Nagelkerke R 2 , 0.661) contained four variables: age, the time when EN therapy was initiated, the serum Ca 2+ level on admission to hospital, and the SOFA score on day 1 (Table 4 ). All four coefficients were statistically significant. Compared with the patients in the EEN group, the patients who began EN therapy beyond 72 h after onset had a much higher probability of pancreatic infection. Calibration of the model determined quantitatively by measures such as the HosmerLemeshow (HL Chi-square, 15.451; P = 0.051) goodness-of-fit statistics showed that the model was able to assign appropriate risk among the patients whose experience it simulated.
The significant prognostic variables for mortality obtained by univariate analysis were as follows: the APACHE II and SOFA scores on days 1-3; the serum CRP level on day 3; the Ranson score; the serum Ca 2+ level on admission to hospital; and the platelet level on admission to hospital. The final multivariate logistic regression model for mortality (logistic regression Chi-square, 28.945, P o0.001; Cox and Snell R 2 , 0.267; Nagelkerke R 2 , 0.703) contained three variables: the platelet level on admission to hospital, the serum Ca 2+ level on admission to hospital, and the SOFA score on day 1 (Table 4) ; only the SOFA score on day 1 was statistically significant. Calibration of the model determined quantitatively by measures such as the Hosmer-Lemeshow (HL Chi-square, 1.210; P = 0.997) goodness-of-fit statistics showed that the model was able to assign appropriate risk among the patients whose experience it simulated.
DISCUSSION
Compared with PN therapy, the advantages of EN therapy have been demonstrated in a large number of animal experiments and clinical trials. [9] [10] [11] [12] However, the optimal time to begin EN therapy has not reached consensus. The results of this study suggest that EN should be initiated within 72 h after AP onset. Compared with the DEN therapy, EEN therapy can accelerate the recovery of disturbed homeostasis and reduce the incidence of pancreatic infection, mortality, length of stay and the need for mechanical ventilation. Moreover, the time when EN therapy was initiated was a prognostic variable for pancreatic infection.
In the early phase of AP, SIRS, blood redistribution and fasting damage gut function, and a previous study demonstrated that bacteraemia in AP can be detected as early as day 4 after AP was diagnosed. 21 In addition, in a sub-study of a randomised, placebocontrolled, double-blind, multi-centre trial on probiotic prophylaxis in 296 adult patients with predicted severe AP, it was found that the serum concentration of intestinal fatty acid-binding Early enteral nutrition in acute pancreatitis L Zou et al protein (a parameter for enterocyte damage) in the first 72 h was higher in those patients who developed bacteraemia or organ failure. 28 Compared with delayed EN therapy, EN administered within 48 h after admission was associated with a significant 24% reduction in infectious complications and a 32% reduction in mortality. 29 A systematic review of 11 studies containing 775 patients revealed that EN therapy initiated within 48 h after admission improved clinical AP outcomes by reducing the risk of infections, organ failure, hyperglycaemia and mortality and shortening the LOS in severe AP patients, whereas there were no significant differences when nutrition support was initiated after that time. 18 Our results were in accordance with the above studies, but our EN therapy was initiated earlier.
There are two overlapping phases in AP's dynamic disease process, with two peaks of mortality: death occurs either in the early phase (often within 1 week after onset), from SIRS and/or organ failure, or in the late phase (beyond 1 week after onset), owing to various infection complications. 7 For management in the early phase of AP, organ function maintenance and infection prevention are the emphases. 30, 31 In the event of any indications of certain organ injuries, measures should be taken such as CRRT for AKI, mechanical ventilation for ARDS and so on. As such, when acute gastrointestinal injury occurs, 16 what can we do for these patients? Many studies have demonstrated that gut function is damaged in the course of AP, even as early as 48-72 h after onset. 21, 29 As the 'motor' of MODS, 32 gut dysfunction is known to be associated with adverse outcomes in critically ill patients, including those with AP. 33 Therefore remedies should be implemented early, and EN has been demonstrated to be the key.
It is noted that nutrition management in AP should aim primarily at maintaining gastrointestinal function, and the gut should be roused by enteral feeding. 34 In other words, enteral feeding is aimed more at resuscitating the gut than supplying energy. Our results showed that patients in the EEN group recovered more quickly than did those in the DEN group, as represented in Table 2 . On the first 3 days after admission, the APACHE II score, SOFA score, serum CRP and albumin concentration and CLI were similar in the two groups, and all decreased gradually over the observed days. However, on the third day after EN administration, we found that these parameters in the EEN group had improved over those in the DEN group; there were significant differences in APACHE II score, the serum CRP concentration and CLI. For bowel wall thickening, we also obtained similar results. Compared with delayed enteral feeding, early enteral feeding can promote AP recovery, and it can be considered a fast-track treatment.
The gut, as an immune and endocrine system organ, contains a great deal of mucosa-associated lymphoid tissue in the submucosa, which produces many different inflammatory mediators that promote the development of SIRS in the early phase of AP. 35 EN can rouse the gut to disturb this course and reduce the rate of organ failure. 34 In our study, the incidence of organ injury was higher in the DEN group, although there was no significant difference in systemic complications between the two groups, which may have been influenced by the study sample size.
In addition, many studies have demonstrated that the bacteria giving rise to infection complications is gut-originated in the late phase of AP, as a consequence of intestinal barrier dysfunction. 21, 36 If gut-originated infection loses control, various infectious complications will turn up, leading to septic shock and MODS. Nutrients are crucial to the maintenance of intestinal barrier function, and nutrition absorbed directly from the gut lumen is an important supplement to that from blood circulation for intestinal epithelial cells. Because of insufficient effective circulatory volume, the gastrointestinal tract is typically inactivated in early AP, leading to lower nutrition supply. If intestinal mucosal epithelial cells cannot obtain sufficient nutrition from the gut lumen, they starve, leading to the loss of the integrity of the gut barrier. 37 EN can protect and repair the intestinal mucosal barrier and reduce gut-originated infections and mortality when EN is initiated at the proper time, 9-15 which explains our results. In infection prevention, prophylactic antibiotics and probiotics are very popular, but there is also a great deal of controversy. [5] [6] [7] All of our study patients received prophylactic antibiotics but no probiotics. For PN, our patients did not receive it in the early phase of AP, because we believe that permissive hypo-calories are reasonable in the early phase. In addition, PN may negatively affect the recovery of damaged homeostasis. All of the above factors were kept uniform, so they did not influence the results of the study.
As a retrospective analysis, this study had some limitations. First, certain valuable parameters could not be acquired, such as duration of abdominal pain, accurate duration of SIRS and others, and the time of CT examination could not be kept uniform. Moreover, because of the small sample size and single-centre design of this study, definite conclusions cannot be drawn from our results; our study simply provides an idea for further research. Its accuracy should be tested further with larger samples and multi-centre randomised controlled research.
In conclusion, compared with DEN therapy, EEN therapy can reduce the incidence of pancreatic infection, accelerate the recovery of disturbed homeostasis and improve the clinical outcomes of AP patients. Therefore, for AP patients, if the anticipated duration of fasting is beyond 5-7 days, enteral nutrition should be initiated within 72 h after onset. Early enteral nutrition in acute pancreatitis L Zou et al
